209747-05-7

Basic information

• Product Name: Tolterodin hydrogen tartrate
• Synonyms: Tolterodin hydrogen tartrate;Tolterodin tartrate;(R)-Tolterodine L-tartrate
• CAS NO: 209747-05-7
• Molecular Formula: C26H37NO7
• Molecular Weight: 475.57448
• Mol File: 209747-05-7.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 442.2 °C at 760 mmHg
• Flash Point: 192.1 °C
• Appearance: /
• CAS DataBase Reference: Tolterodin hydrogen tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Tolterodin hydrogen tartrate(209747-05-7)
• EPA Substance Registry System: Tolterodin hydrogen tartrate(209747-05-7)

Safety Data

• Hazardous Substances Data: 209747-05-7(Hazardous Substances Data)

Usage

General Description

Tolterodine hydrogen tartrate is a chemical compound used as an active ingredient in medications to treat overactive bladder. It works by relaxing the muscles of the bladder, reducing the urge to urinate frequently and the incidents of incontinence. Tolterodine hydrogen tartrate is part of a class of drugs known as antimuscarinics, which block certain nerve signals in the body that are responsible for causing overactive bladder symptoms. It is available in oral tablet and extended-release capsule forms and is usually taken once or twice daily, as prescribed by a healthcare professional. Common side effects of tolterodine hydrogen tartrate include dry mouth, constipation, and headache. It is important to follow the dosage and usage instructions provided by a doctor to ensure safe and effective treatment.

Upstream product

• 837376-36-0 3-(2-hydroxy-5-methylphenyl)-N,N-diisopropyl-3-phenylpropan-1-aminium bromide 
• 87-69-4 L-Tartaric acid 
• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 147-71-7 D-tartaric acid 
• 124937-51-5 (R)-(+)-tolterodine 
• 897314-72-6 (+/-)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propanamide 
• 1043911-42-7 N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propylamine L-tartrate 
• 854306-67-5 methyl 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropionate 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 
• 389068-22-8 N,N-diisopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropylamine 
• 854306-68-6 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 851789-43-0 3-phenyl-3-(2'-hydroxy-5'-methyl)phenylpropanol-1 
• 4850-49-1 1-phenyl-1,3-propanediol 

Downstream Products

• 848768-06-9 (R)-3-[2-(benzyloxy)-5-methylphenyl]-N,N-diisopropyl-3-phenylpropan-1-amine 
• 380636-50-0 (R)-5-hydroxymethyl tolterodine fumarate salt 
• 156755-37-2 {4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]phenyl}methanol 
• 214601-54-4 (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal 
• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 

Relevant articles and documents

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF

The present invention relates to an improved process for the preparation of Tolterodine or salts thereof, which comprises the use of 3-(2-methoxy-5-methylphenyl)-3-phenylpropyl methane sulfonate.

PROCESS FOR THE PREPARATION OF N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)- 3-PHENYL PROPYLAMINE AND ITS SALTS STARTING FROM A NOVEL INTERMEDIATE

The invention concerns an improved process for the preparation of tolterodine (N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propyl amine) and its salts, in particular for the preparation of the tartrate salt, and more particularly for the (+)-(R) enantiomer of tolterodine L-tartrate, starting from a novel intermediate, N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3- phenyl-2-propenamide, which can be used as pure Z or E isomer or as a mixture of Z and E isomers. When the target is the preparation of the enantiomer (R)-(+)-(N,N- diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine) and diastereomeric crystallization of suitable compound is applied, the present invention covers also the use of racemisation of undesired (S)-(-)- (N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3 -phenyl propylamine) enantiomer and its recycle in the process.